In a potential setback for Roche (RHHBY), five patients taking its new Hemlibra hemophilia treatment have died, raising uncertainty about the safety of the medication, even though the company maintained its drug did not cause any of the deaths.

Over the past two years, one patient died during a late-stage clinical trial and the others died while taking Hemlibra as part of a compassionate use program, which provides access to experimental medicines before regulatory approval.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • May I observe that people wonder wht ‘PHARMA” is against these right-to-try initiatives? How about ‘stuff happens?” – “Over the past two years, two patients died while taking Hemlibra as part of a compassionate use program, which provides access to experimental medicines before regulatory approval.”
    And so Roche made the drug available and what is their reward? I’m not trying to deify them but nothing complicated is ever a zero sum game. The fact of there events is and will be counted against them. I would say how dumb did the US House have to be to pass something like that but …. why ask?

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy